Form 4 for MLTX MoonLake Immunotherapeutics

Accepted 2026-04-10 18:06:45 ET · period of report 2026-04-09 · accession 0001213900-26-042629 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-04-10 18:06	2026-04-09+	MLTX	Bodenstedt Matthias	CFO	S - Sale	$18.95	-87.8K	1.19M	-7%	-$1.66M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A ordinary shares, par value $0.0001 per share	2026-04-09	S	D	85,870	$18.94	1,190,435	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.340 to $19.455. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2	Common	Class A ordinary shares, par value $0.0001 per share	2026-04-10	S	D	1,925	$19.51	1,188,510	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person. (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.560. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.